Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05004974

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Sintilimab Combined With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer: an Open Label, Phase II Trial

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions Advanced Non Small Cell Lung Cancer

Interventions Pemigatinib Sintilimab

Updated 5 times since 2021 Last updated: Mar 7, 2024 Started: Apr 26, 2022 Primary completion: Sep 1, 2023 Completion: Sep 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05004974, this PHASE2 trial focuses on Advanced Non Small Cell Lung Cancer and remains actively recruiting participants. Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University, it has been updated 5 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE2
Oct 2023 — Apr 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Oct 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Second Affiliated Hospital, School of Medicine, Zhejiang University
The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Data source: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Yiwu, China